Plus Therapeutics Outlines 2026 Milestones for REYOBIQ Clinical Program and CNSide Commercialization.
ByAinvest
Thursday, Jan 22, 2026 9:13 am ET1min read
PSTV--
Plus Therapeutics, a clinical-stage pharmaceutical company, has outlined its 2026 goals, focusing on advancing the REYOBIQ clinical program and scaling up commercialization of its CNSide diagnostic platform. The company aims to complete commercial manufacturing scale-up for REYOBIQ, begin enrollment in a pediatric brain cancer trial, and achieve commercial milestones for CNSide. With a $15 million upsized offering, Plus Therapeutics expects to extend its cash runway through 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet